06/05/2014 12:19 PM Posted by: Dr. H. Alejandro Preti


Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL
Early findings from the phase III RESONATE study indicate that ibrutinib produces durable tumor responses and marked improvement in survival over standard ofatumumab for patients with relapsed chronic lymphocytic leukemia. At a median follow-up of 9.4 months, response rates were dramatically higher in the ibrutinib arm compared to the ofatumumab arm, and ibrutinib was associated with an 80% lower risk of disease progression and a 57% reduced risk of mortality compared to ofatumumab.

Second-Line Treatment With Ramucirumab Plus Standard Docetaxel Extends Overall Survival in Advanced Lung Cancer
Patients with stage IV non–small cell lung cancer who relapsed after initial platinum-based therapy had extended overall survival with a combination of the antiangiogenic agent ramucirumab and standard chemotherapy with docetaxel, compared to patients receiving docetaxel plus placebo in the phase III REVEL study.

Lenvatinib Yields High Response Rates, Delays Progression in Patients With Radioiodine-Resistant Differentiated Thyroid Cancer
A phase III study presented at the 2014 ASCO Annual Meeting found that the oral targeted drug lenvatinib is highly effective among patients with differentiated thyroid cancer resistant to standard radioiodine therapy. Patients experienced rapid, high response rates and an improvement in progression-free survival of more than 14 months after being treated with lenvatinib.

Investigational Anti–PD-L1 Antibody Demonstrates Promising Activity in Certain Patients With Metastatic Bladder Cancer
In a phase I open-label study, the investigational anti–programmed death-ligand 1 (PD-L1) monoclonal antibody MPDL3280A demonstrated promising overall response rates in patients with previously treated metastatic urothelial bladder cancer whose tumors were characterized as PD-L1–positive.

Patients With Metastatic Colon Cancer Respond to New Combination Therapy, Phase IB Study Shows
In a new study presented at the ASCO Annual Meeting, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vemurafenib, cetuximab, and irinotecan. The phase IB trial examined the BRAF V600 mutation, which is present in 5% to 10% of patients with colorectal cancer.

Temsirolimus May Benefit Patients With Rhabdomyosarcoma.

Medscape (6/6, Nelson, 192K) reports that research indicates “when temsirolimus (Torisel) is added to chemotherapy in the treatment of rhabdomyosarcoma, the most common soft tissue sarcoma in children, event-free survival is improved.” The findings were presented at the American Society of Clinical Oncology meeting.

Study: Necitumumab Modestly Improved Survival In Squamous NSCLC.

MedPage Today (6/6, Phend, 205K) reports that research presented at the American Society of Clinical Oncology meeting indicated that “the novel anti-EGFR monoclonal antibody necitumumab modestly improved survival in squamous non-small cell lung cancer (NSCLC) in a pivotal trial, but many called the effect too small to count.” Researchers found that “adding the drug to a standard chemotherapy regimen improved overall survival by 16% (P=0.012).” 

Plenary: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer

The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease.

Plenary: Adjuvant Exemestane With Ovarian Function Suppression Better at Preventing Breast Cancer Recurrence Than Tamoxifen

A joint analysis of two phase III trials (TEXT and SOFT) demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen, when either was given with ovarian function suppression to premenopausal women with hormone-sensitive cancers.

Belinostat Moves Forward in Trials for Two Aggressive Cancers

Belinostat is in development as a targeted HDAC inhibitor that is being studied in small cell lung cancer for its ability to synergize with combination therapy, and in peripheral T-cell lymphoma as a single agent.

Enzalutamide Plus Abiraterone May Benefit Certain Patients With Metastatic Prostate Cancer.

MedPage Today (6/4, Phend, 205K) reports that research presented at the American Society of Clinical Oncology meeting indicated that “a combination attack on androgens in metastatic prostate cancer resistant to initial hormone therapy drove down testosterone levels and appeared safe.” The study indicated that “enzalutamide (Xtandi) plus abiraterone (Zytiga) dropped blood and bone marrow androgens down to undetectable levels for 80% of such patients, reported Eleni Efstathiou, MD, PhD.” 

Study: Apatinib Significantly Prolonged OS In Patients With Advanced Gastric Cancer Compared With Placebo.

Cancer Network (6/4, Lawrence) reports that research presented at the American Society of Clinical Oncology meeting indicated that “the vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor apatinib significantly prolonged overall survival in patients with advanced gastric cancer compared with placebo.” The study “included patients with advanced gastric cancer who had failed prior second-line chemotherapy.” Participants “were randomly assigned 2:1 to 850-mg apatinib or placebo.” 

Share Categoried under:  Cancer NewsClinical Trials
Blog Search


arrow View All arrow


June 2014 (1)
February 2014 (1)
August 2013 (1)
June 2013 (1)
April 2013 (2)
February 2013 (1)
October 2011 (4)
September 2011 (1)
August 2011 (2)
April 2011 (3)
March 2011 (2)
February 2011 (1)
November 2010 (1)
June 2010 (1)
March 2010 (1)
January 2010 (1)
December 2009 (1)
November 2009 (2)
October 2009 (1)
Captavi QixSuite™ - Hosted Marketing Automation Software ©